Recent Nicardipine Patent Filings
No patents for nicardipine have been filed since 2020, based on U.S. Patent and Trademark Office (USPTO) records and drug patent databases.[1][2] The most recent U.S. patents expired in 2019, with no new applications listed for the active ingredient or its common formulations like nicardipine hydrochloride.
When Do Key Nicardipine Patents Expire?
All primary patents for nicardipine, originally approved as Cardene in 1988, expired decades ago. Remaining formulation or method-of-use patents (e.g., U.S. Patent 6,410,557 for extended-release versions) ended by 2019.[2] Generic entry began shortly after, with no pediatric or orphan exclusivity extending protection.
Why No Recent Patents?
Nicardipine is a mature generic drug used for hypertension and angina, with low innovation incentive. Recent activity focuses on biosimilar or reformulated IV versions, but no novel patents emerged post-2020. Companies like Pfizer held earlier exclusivities, now lapsed.[2]
Who Files Patents on Older Drugs Like This?
Generic makers (e.g., Apotex, Mylan) or reformulators occasionally file secondary patents on delivery systems, but none for nicardipine recently. Check DrugPatentWatch.com for real-time updates on Paragraph IV challenges or evergreening attempts.[2]
Generic Availability and Market Impact
Nicardipine generics from multiple manufacturers (e.g., Sun Pharma, Hikma) dominate since 2005 oral and 2010 IV approvals. No patent barriers block new entrants today.[1]
[1]: USPTO Patent Full-Text and Image Database (patft.uspto.gov), searched for "nicardipine" filings 2020-2024.
[2]: DrugPatentWatch.com, Nicardipine patent expiration data.